Searched for
MEDICINES FOR MALARIA VENTURE
These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...- For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 29%In the current phase of market volatility, the only solace to be derived is from market history. And history tells us that, just like good ...
- Oxford University strikes new malaria vaccine pact with Serum Institute of IndiaOxford University and Serum Institute of India are collaborating on a new malaria vaccine, R78C. This partnership aims to create a more eff...
- Zydus Cadila receives orphan drug status from USFDA for its novel malaria drugDrug maker Cadila Healthcare (Zydus Cadila), on Thursday said its antimalarial drug ZY19489 (MMV253), currently in development together wit...
- Cipla launches anti-malaria drug for young childrenThe company introduced 100 mg Artesunate Rectocaps/Rectal Artesunate Suppositories (RAS), a life-saving, pre-referral intervention for the ...
- Zydus partners Swiss non-profit for malaria drug developmentUnder its latest tie-up, Zydus will lead the development of the compound, called MMV674253, while MMV will provide scientific expertise.
- Cipla Ltd, Strides Arcolab signs collaboration agreements with Medicines for Malaria VentureCipla and Strides will develop a product building on the clinical studies led by TDR, the special programme for research and training in tr...
- Malaria research requires USD 8.3 billion: ReportThe study warns that R&D investments are critical, given the emergence of drug resistance in the malaria parasite and insecticide resistanc...
- Drug to offer 'single-dose' malaria cure foundScientists claim to have discovered a drug that could cure all strains of malaria with a single oral dose and also block transmission of th...
- Cadila Pharmaceuticals and Novavax to develop malaria vaccine using virus like particle technologyCadila Pharma and Novavax to develop new malaria vaccine using VLP technology. ICGEB also to partner them in the project.
- Ranbaxy gets nod for first drug developed by Indian pharma coThe proposed launch could provide a boost to Ranbaxy’s revenues as this combination drug will be cheaper and easier to consume, compared to...
- Tata co ties up with Genzyme, Medicines for Malaria VentureAdvinus Therapeutics, a Bangalore-based research pharma company promoted by the Tata group, has announced a new collaboration with Genzyme ...
- Ranbaxy set to launch India's first malaria drugDrug major Ranbaxy has successfully completed the phase II clinical trials for the first malaria drug being developed in the country.
- Ranbaxy completes phase II trials for anti-malaria drugRanbaxy has succesfully completed the phase II clinical trials for the first malaria drugs being developed in India since many decades and ...
- Uganda woos Indian pharma firmsUganda wooed Indian pharmaceutical companies to invest and set up manufacturing facilities there by offering lucrative tax sops.
- Ranbaxy to hive off drug discovery research bizRanbaxy Laboratories has decided to hive off its drug discovery research (DDR) operation into a separate company and plans to list the new ...
- Ranbaxy to hive off R&D bizRanbaxy Laboratories is planning to hive off the research and development (R&D) of its new chemical entities (NCEs) into a separate company.
- WHO agency, Ranbaxy part ways from drug developmentWHO agency Medicines for Malaria Venture and Ranbaxy were involved in a four year-long joint development programme for an anti-malarial com...
- Ranbaxy net grows 20% to Rs 121 crRanbaxy has reported a 20% increase in net profit in the quarter ended June 30, ‘06 to Rs 121 crore from Rs 101.3 crore in the correspondin...
Load More
